Actinic Keratosis News and Research

RSS

Actinic keratosis, also known as solar keratosis, is a dry, scaly patch of skin that presents as a result of chronic exposure to sunlight. Most people with the condition do not report significant symptoms, although the condition can progress to a type of skin cancer, squamous cell carcinoma, in severe cases without treatment.

Survey reveals the limited knowledge about actinic keratosis among most people

Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, presented today the results of a survey revealing that 85% of respondents are unaware of the existence of actinic keratosis (AK).

25 May 2023

Low-cost handheld device could cut the rate of unnecessary skin biopsies

Skin biopsies are no fun: doctors carve away small lumps of tissue for laboratory testing, leaving patients with painful wounds that can take weeks to heal.

5 May 2022

EORTC partners with Pierre Fabre to support patients with stage 2 melanoma

European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma.

29 Jun 2021

Study emphasizes the importance of whole body skin evaluations in older patients

In a study of 552 adults aged 70 to 93 years old, 80% of participants had at least one skin disease that required treatment, and the most common conditions were fungal skin infections, rosacea, actinic keratosis, and eczema. ?

5 Aug 2020

New method for discovering potential cancer-treating compounds

A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.

4 Dec 2019

New screening method can rapidly discover potential cancer-treating compounds

Scientists at Scripps Research have developed a method for rapidly discovering potential cancer-treating compounds that work by resurrecting anti-tumor activity in immune cells called T cells.

3 Dec 2019

Skin diseases may be more prevalent than previously thought

Skin diseases are ranked as the fourth most common cause of human illness, but many affected people do not consult a physician. A new Journal of the European Academy of Dermatology and Venereology study estimates the prevalence of skin diseases outside the typical medical setting.

20 Mar 2019

New study shows added benefit of ingenol mebutate for patients with actinic keratosis

Already in 2013, the German Institute for Quality and Efficiency in Health Care examined in an early benefit assessment whether ingenol mebutate offers greater benefit than the appropriate comparator therapy for patients with actinic keratosis.

7 Dec 2018

French scientists develop new wearable laser that eradicates skin conditions

French scientists at ‘Texinov Medical Textiles’, have developed a knitted laser fabric that blasts the skin with light, giving treatment to inflamed skin or lesions over a 2 and a half hour appointment.

21 Feb 2018

Generic skin cream may reduce squamous cell carcinoma risk

New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.

3 Jan 2018

Papillomaviruses linked to UV light promote development of non-melanoma skin cancer

UV radiation has been known for a long time to be a risk factor for the development of skin cancer. Simultaneous infection with human papillomaviruses (HPV) has also been suspected to promote skin cancer, particularly in organ transplant recipients.

30 Nov 2017

Combination therapy holds great promise to clear precancerous skin lesions

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patients participating in a clinical trial.

19 Dec 2016

Study shows new drug combination effective in treating precancerous skin lesions

A combination of two topical drugs that have been in use for years triggers a robust immune response against precancerous skin lesions, according to a new study. The research, from Washington University School of Medicine in St. Louis and Harvard Medical School, shows that the therapy activates the immune system's T cells, which then attack the abnormal skin cells.

21 Nov 2016

Common bacteria on human skin may offer protection against diseases

There are more and more examples of the ways in which we can benefit from our bacteria. According to researcher Rolf Lood from Lund University in Sweden, this is true for the skin as well.

11 Nov 2016

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Cipher Pharmaceuticals Inc. today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and Actikerall from Almirall S. A., a Spanish pharmaceutical company. Both products have been approved by Health Canada.

6 May 2015

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas.

20 Jan 2015

New actinic keratoses data presented at the 15th World Congress of Cancers of the Skin

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato® (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased.1 The data also confirm two treatment cycles of Picato® are well tolerated by patients.2

4 Sep 2014

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months.

25 Jul 2014

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014.

20 May 2014

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex, Inc. reports financial results for the three months ended March 31, 2014 and announces LCA-Vision stockholder approval of PhotoMedex's previously announced acquisition of all outstanding shares of LCA-Vision, a leading provider of laser vision correction services under the LasikPlus brand.

12 May 2014